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Summary
Hepatitis C virus (HCV) is a primarily hepatotropic virus, but hepatocytes are not the only localiza-
tion of its replication. It is still unclear if extrahepatic HCV replication, measured as the detection of 
HCV RNA negative strand in peripheral blood mononuclear cells (PBMCs) before initiation of treat-
ment, has an influence on therapy response. Detection of HCV RNA in extrahepatic sites for assess-
ment of therapy efficacy is not routinely used in clinical practice. The aim of the study was to evaluate 
whether the replication of HCV in PBMCs affects the rate of sustained virological response (SVR).
The study group comprised 55 patients with chronic hepatitis C, originally treatment naive. They 
were treated with pegylated interferon (PEG-IFN) alpha 2a and ribavirin, with the standard dosing 
schedule. Parallel serum samples for HCV RNA and PBMC samples for HCV RNA negative strand 
were obtained at baseline, at the end of treatment and 24 weeks after finishing therapy.
Undetectable HCV RNA in serum at the end of therapy was found in 48 patients (87.3%), while 
33 patients (60.0%) achieved sustained virological response (SVR) (51% for HCV genotype 1 and 
78% for genotype 3, respectively). Fifteen individuals (31.3%) were relapsers. Factors associated with 
significantly higher rate of SVR were young age, mild or no fibrosis and infection with HCV geno-
type 3. HCV RNA negative strand in PBMCs before treatment was found in 21.8% (12 out of 55 
patients). HCV RNA negative strand was detected at baseline more frequently in patients who later 
achieved SVR. Relapse appeared significantly more often in patients with negative strand at the end 
of therapy: in 2 out of 15 individuals compared to 0 out of 33 patients (p=0.03).
Presence of negative HCV RNA strand in PBMCs before treatment may be suggested as a potential 
marker of good treatment response. Detection of negative strand at the end of therapy is a predic-
tor of relapse.
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Background
Infection with hepatitis C virus (HCV) causes chronic 
hepatitis, which may lead to liver cirrhosis and subsequently 
to hepatocellular carcinoma (HCC). HCV is a primarily 
hepatotropic virus, but hepatocytes are not the only local-
ization of its replication. 
Extrahepatic replication is well recognized and HCV se-
quences have been found, among other sites, in peripheral 
blood mononuclear cells (PBMCs): T-cell and B-cell lines 
and monocytes/macrophages [12,24]. Some studies also 
found replication of HCV in perihepatic lymph nodes, sali-
vary glands, oral epithelial cells, pancreas, adrenal glands, 
thyroid and brain [11,18,19].
HCV is a positive strand RNA virus and negative strand 
acts as a replicative intermediate. Both positive and nega-
tive strands of HCV RNA are found in PBMCs. Whereas 
presence of HCV RNA positive strand may be the result 
of virions adsorption from the serum, detection of negative 
strand confirms the active replication of virus in these cells. 
Average amounts of HCV RNA positive strand are 10 to 
100 times higher than negative strand [12,19].
Persistence of the replicating virus in PBMCs, even if 
HCV RNA is undetectable in serum, may cause infection 
reactivation in the future, particularly under conditions of 
immunosuppression (e.g. long-term steroid therapy, organ 
transplantations, HIV infection). Moreover, it may also 
play a role in pathogenesis of extrahepatic manifestations 
of HCV infection [5].
The current standard of care (SOC) includes combination 
therapy with pegylated interferon alpha 2 and ribavirin. The 
aim of treatment of chronic hepatitis C is the sustained 
suppression of viral replication. Sustained virological re-
sponse (SVR) is assessed 24 weeks after finishing treatment 
and is defined as negative HCV RNA in the serum. De-
tection of HCV RNA in extrahepatic sites for assessment 
of therapy efficacy is not routinely used in clinical practice. 
Several well-known factors influence the SVR rate: age, sex, 
HCV genotype, baseline level of HCV viremia, liver fibro-
sis stage, interleukin (IL)28b polymorphism. The presence 
of HCV RNA negative strand in PBMCs at the end of 
treatment as a factor determining higher risk of viral relapse 
has been confirmed in some studies [3,13,21]. However, 
it is not clear if extrahepatic replication in PBMCs before 
treatment affects the treatment efficacy.
The aim of the study was to evaluate whether the extrahe-
patic replication of HCV affects therapy response.
Materials and Methods
The study group comprised 55 patients with chronic hepati-
tis C, treatment naive, 28 females and 27 males, aged 24-68 
years (mean 47.3). All the patients were anti-HCV positive, 
HCV RNA positive. HCV genotype 1 was detected in 35 
patients (63.6%), genotype 3 in 18 individuals (32.7%) and 
genotype 4 in 2 patients (3.6%). All the individuals were 
treated with pegylated interferon alpha and ribavirin, with 
the standard dosing schedule regarding HCV genotype and 
body weight. All patients were receiving peginterferon alfa-
2a 180 µg once weekly (Pegasys; Hoffmann-La Roche, Ba-
sel, Switzerland) combined with ribavirin (Copegus; Hoff-
mann-La Roche, Basel, Switzerland) in the dose of 1000 
mg/day if their body weight was <75 kg or 1200 mg/day if 
their body weight was ≥75 kg. Duration of treatment was 48 
weeks for genotypes 1 and 4, and 24 weeks for genotype 3.
Baseline HCV RNA in serum ranged from 1.4 x 103 to 
11.1 x 107 IU/ml. Inflammatory activity in liver histologi-
cal examination was 0-3 (mean 1.97), and staging was in 
the range 0-4 (mean 2), according to the METAVIR score.
Parallel serum samples for HCV RNA and PBMC samples 
for HCV RNA negative strand were obtained at baseline, at 
the end of treatment and 24 weeks after finishing therapy. 
Anti-HCV antibodies in serum were analyzed using a 
2nd generation anti-HCV kit (Organon Teknika, Dublin, 
Ireland), qualitative and quantitative HCV RNA in serum 
by RT-PCR (Abbott RealTime HCV (Abbott Molecular 
Inc.), lower limit of detection 30 IU/ml). HCV genotype 
was determined by INNO-LiPA test (Innogenetics).
Peripheral blood mononuclear cells (PBMC) (3x 105-106 
cells) were isolated from blood by centrifugation over a 
density gradient and RNA was extracted by means of a 
modified guanidinium thiocyanate-phenol/chloroform 
technique using a commercially available kit (TRIZOL 
LS, Gibco/BRL). The specificity of our real-time RT-PCR 188
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assay for the detection of negative-strand HCV RNA was 
ascertained by conducting cDNA synthesis at a high tem-
perature with the thermostable enzyme Tth (Applied Bio-
systems). Descriptions of the Tth-based assay and its real-
time modification have been published elsewhere [10]. 
The strand-specific assay is capable of detecting ~100 viral 
genomic eq/mL of the correct negative strand. Although 
the assay is quantitative over a wide range of template, the 
results were commonly close to the level of detection and, 
thus, were reported only as being either positive or negative.
Data were compared using the parametric Student’s t test 
and nonparametric Mann-Whitney U test and Chi-square 
test. Spearman’s coefficient was used to calculate the corre-
lations. Values of p ≤ 0.05 were considered to be statistically 
significant. Calculations were performed using Statistica 64 
version 10 for Windows (StatSoft Inc., Tulsa OK USA).
results
Negative HCV RNA in serum at the end of treatment, 
meaning end of treatment response (ETR), was found 
in 48 patients (87.3%) and sustained virological response 
(SVR) at 24 weeks after therapy in 33 patients (60%); 
51% for HCV genotype 1 and 78% for genotype 3, re-
spectively. Relapse of replication at follow-up 24 weeks 
after the end of therapy was detected in 15 individuals 
(31.3%).
Comparison of 33 patients with SVR with 22 non-SVR 
patients, including age, sex, body weight, HCV genotype, 
quantitative HCV RNA, grading and staging, is presen-
ted in Table 1. Rates of HCV RNA in serum and HCV 
RNA negative strand in PBMCs at certain time points of 
observation are shown in Fig. 1.
Fig. 1. Rates of detectable HCV RNA in serum and HCV RNA negative strand in PBMCs during observation [% of patients]
Table 1. Comparison of groups with and without sustained virological response.
SVR
n=33
non-SVR
n=22
Statistical tests
Age; mean (range) 44.27 (24-66) 51.72 (28-68) t=2.57; p=0.013
Male : female 16:17 12:10 Chi-square=0.19; p=0.66
Body weight 80.33 80.81 t=0.1; p=0.92
HCV genotype (%)
1 18 (55) 17 (77) Chi-Square=39;
3 14 (42) 4 (18) p<0.001
4 1 (3) 1 (5)
HCV RNA, quantitative [IU/ml] 14.2 x 106 9.47 x 106 t=-0.81; p=0.52
ALT; mean (range) [IU/l]  96 (24-317) 81 (20-221) t=-0.9; p=0.37
Grading; mean (range) 1.9 (0-3) 2.11 (1-3) t=1.1; p=0.3
Staging; mean (range) 1.82 (0-3.5) 2.28 (1-3.5) t=2.1; p=0.039
SVR, sustained virological response; ALT, alanine transaminase189
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A parallel significant decline of detectable HCV RNA in 
serum and HCV RNA negative strand in PBMCs was 
observed at the end of treatment, compared to baseline. 
Also relapse of HCV replication in serum 24 weeks after 
therapy was parallel to re-appearance of HCV RNA ne-
gative strand in PBMCs.
Among 33 individuals who achieved SVR, HCV RNA 
negative strand before start of treatment was detected 
in 10 patients, compared to only 2 patients among 15 
without SVR (30.3% vs 9.1%). Twenty-four weeks after 
the end of therapy HCV RNA negative strand was de-
tected 3-fold more frequently in the non-SVR group 
versus the SVR group (18.2% vs 6.1%). Comparison of 
HCV RNA negative strand rates in PBMCs in SVR 
and non-SVR groups at particular time points of obse-
rvation is shown in Table 2.
Comparison of ETR and SVR rates in groups with and 
without HCV RNA negative strand before treatment is 
shown in Table 3.
Among 55 individuals there were 48 patients (87.3%) 
with negative HCV RNA in serum at the end of the-
rapy. Relapse of HCV replication after the end of tre-
atment was observed in 15 of them (31.3%). Negative 
strand in PBMCs at the end of therapy was detected in 
2 among 15 of these patients (13.3%). Negative strand 
at the end of therapy was observed significantly more 
often in patients with relapse than with SVR (2/15 vs 
0/33; p=0.03).
 In 2 patients, who achieved SVR, both infected with HCV 
genotype 3, negative strand in PBMCs was detected 6 
months after the end of treatment. Repeated assessment 
was performed 36 months after therapy and HCV RNA 
in serum was still negative.
discussion
Treatment with pegylated interferon alpha and ribavirin 
caused the elimination of HCV RNA negative strand from 
PBMCs in parallel with elimination of HCV RNA from 
serum. 
Based on former studies there was evidence of persisting 
HCV RNA negative strand in PBMCs despite sustained 
elimination of HCV RNA from serum. The majority of 
these studies assessing HCV replication in PBMCs and 
its influence on therapy outcome were conducted in the era 
of recombined interferon alpha [13,16,18,23]. Our finding 
may be proof of the stronger action of pegylated interferon 
compared to recombinant IFN. PEG-IFN might be able to 
eliminate the extrahepatic reservoir, as no negative strand 
was detected at the end of therapy in the group with SVR. 
Pugnale et al. analyzed the dynamics of decline of HCV 
RNA in PBMCs on treatment with pegylated interferon 
alpha and ribavirin. Fast viral decay in PBMCs was asso-
ciated with sustained virological response, but viral kine-
tics in PBMCs added only minor predictive information 
compared with kinetics in plasma [17].
In our analysis, well-known predictive factors – younger 
age, less advanced fibrosis and infection with HCV geno-
type 3 – were associated with a significantly higher rate 
of SVR (p<0.05 for each parameter), as in many other 
studies [1,6,14].
As previously reported, the presence of negative HCV 
RNA strand in PBMCs at the end of treatment is a pre-
dictor of replication relapse [8,15,18]. Our observation was 
consistent with other authors.
In some studies, also presence of HCV RNA negative 
strand before treatment was suggested to be a negati-
Table 2. Rates of negative HCV RNA strand in PBMCs in SVR and non-SVR groups
SVR (%) non-SVR (%) Chi-square, p
Baseline 10/33 (30.3) 2/22 (9.1) 2.33, p=0.13
EOT 0/33 (0.0) 2/22 (9.1) 2.85, p=0.09
FU24 2/33 (6.1) 4/22 (18.2) 1.57, p=0.21
EOT, end-of-treatment; FU24, follow-up 24 weeks
Table 3. Rates of ETR and SVR in groups with and without HCV RNA negative strand at baseline
Negative strand at baseline 
(n=12; 21.8%)
Without negative strand at baseline 
(n=43; 78.2%) Statistical tests
ETR (yes/no) 12 (100%)/0 (0%) 36 (83.7%)/7 (16.3%) Chi-square=2.24; p=0.13
SVR (yes/no) 10 (83.3%)/2 (16.7%) 23 (53.5%)/20 (46.5%) Chi-square=3.48; p=0.062
ETR, end of treatment response; SVR, sustained virological response190
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An additional finding of our study was the low rate of 
HCV RNA negative strand in PBMCs before treatment 
(18%) compared to other studies: 92% in children [8], and 
40% in adults with chronic hepatitis C [7]. An influence 
of method sensitivity cannot be excluded [9]. 
Persistence of negative strand in PBMCs more than 24 
weeks after the end of therapy may not mean the risk of 
late relapse of HCV replication in serum, as in 2 patients 
after 36 months of post-treatment observation HCV RNA 
in serum is still negative.
In summary, our findings suggest that examination of ne-
gative HCV RNA strand in PBMCs may have some im-
pact for prediction of treatment success. With respect to 
the role of well-established response predictive factors, our 
observation suggests that HCV replication in PBMCs may 
have a positive influence on immune mechanisms enhanced 
by antiviral therapy. Extrahepatic replication of HCV is an 
intriguing phenomenon and its evaluation brings essential 
information for knowledge about the pathogenesis and 
natural history of HCV infection.
The most significant limitations of our study include the 
small study group, particularly with detectable negative 
HCV RNA strand and no data concerning the polymor-
phism of IL28b, as in the period of conducting the study 
it was not yet an established prognostic factor in clinical 
practice.
ve prognostic factor [2]. Surprisingly, in our study pa-
tients who had detectable HCV RNA negative strand 
in PBMCs before treatment had a higher rate of SVR 
(p=0.062). This potentially beneficial influence of nega-
tive strand presence on SVR rate is unclear. Different 
hypotheses of mechanisms concerning the biology of 
HCV infection, host immune response and IFN alpha-
-mediated response have been proposed over the last 
few years. PBMCs are important target cells for IFN; 
they may express IFN receptors at a level comparable 
with liver cells [22]. It was demonstrated that pegylated 
interferon alpha modulates the expression of approxi-
mately 1000 genes in PBMC in vitro and in vivo [20]. 
There are observations suggesting presence of distinct 
variants of HCV in different compartments, such as pla-
sma, PBMCs, and brain. PBMC-specific variants might 
attenuate the cell-mediated immune response. PEG-
-IFN therapy, suppressing HCV replication in PBMCs, 
might however antagonize this negative effect on the 
immune response. Moreover, negative strand, as a repli-
cative intermediate for HCV, may induce viral protein 
expression and subsequently stimulate an anti-HCV 
immune response [4,24].
Possibly, PBMC infection by HCV genotypes 2 and 3, 
highly sensitive to interferon alpha, was more predictive 
of the treatment response than was the presence of these 
genotypes in plasma. However, we did not determine the 
HCV genotype of HCV extracted from PBMCs.
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